You are here

System for documenting and tracking skin lesions

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41EB032304-01A1
Agency Tracking Number: R41EB032304
Amount: $252,388.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIBIB
Solicitation Number: PA21-262
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-07-01
Award End Date (Contract End Date): 2023-06-30
Small Business Information
Potomac, MD 20854-1512
United States
DUNS: 108194956
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (202) 368-1216
Business Contact
Phone: (202) 368-1216
Research Institution
BALTIMORE, MD 21218-2680
United States

 Nonprofit College or University

Project Summary
The objective of this STTR proposal is to develop a system for longitudinally tracking the locations and
morphologic changes to all Pigmented Skin Lesions on the patient’s body. The proposed software will build on
a previously developed Total Body Photography (TBP) system, called Lumo Scanner, that can provide
unprecedented resolution across the entire body surface. Skin cancers, including both melanoma and non-
melanoma, are the most common type of cancer in the United States. Early-stage identification of suspicious
pigmented lesions (SPLs) in primary care settings can lead to improved melanoma prognosis and a possible 20-
fold reduction in treatment cost. The proposed device significantly reduces the clinicians’ time required for
documenting lesions and for making diagnostic decisions, thereby allowing the healthcare system to better cope
with the forecasted shortages of dermatologists. The proposed technology is novel in that it: 1) provides a
standardized way of referring to lesions’ locations, 2) allows dermatologists to maintain a complete historical
record of every lesion 3) detect significantly changed (evolved) lesions and 4) assists dermatologists in finding
cancerous lesions at their very early stages to improve overall patient prognosis.
The project team has already developed a Total Body Photography (TBP) system that is unlike the commercially
available systems in that it obviates the need for using a dermatoscope and can produce images of sufficient
resolution that can be used for early detection of skin cancers. This device has already received an IRB and
has been installed at Johns Hopkins (JHU) Outpatient Center for its first clinical study. By your reading of this
proposal is under review, JHU’s 100-patient study in which the efficacy of scan-based examinations will be
compared with the efficacy of traditional clinical and dermatoscopic-based skin examinations, is well on its way.
Within this proposal team intends to develop a temporal study tool that can follow all PSLs over time regardless
of participants’ pose and weight changes between scanning sessions. Such a system will enable clinicians to
accurately monitor patients’ PSLs over time, document any changes in previously identified lesions, and detect
new lesions at the point of care. Within, the two phases of this project, the team will also focus on detecting
evolved lesions and optimizing the scanning software to provide a better user interface for following and
diagnosing pigmented skin lesions (PSL) while reducing the amount of time it takes for the dermatologist to fully
document the patients lesions of interest.
Though some literature suggests the epidemy in melanoma is the result of over-screening as evidenced by the
number of deaths not increasing commensurately, others suggest that the low death-rate is the result of better
screening. Regardless, there is unanimous agreement that too many lesions are studied by pathologists. Lumo
Scanner when combined with the facilities developed in this project, will enable technicians perform highly
accurate scans and thus allow the dermatologist to spend less documenting the high-risk patients. Also, this
novel device will enable teledermatology in areas where there is a scarcity of dermatologists. Additionally, the
proposed device can also be used for diagnosing and accurately monitoring the efficacy of therapies for
psoriasis, atopic dermatitis, and other inflammatory skin conditions. Psoriasis and atopic dermatitis are also
serious global problems. In the United States, psoriasis affects about 8 million people while about 31.6 million
people in the United States have some form of eczema, including atopic dermatitis.PROJECT NARRATIVE
The team proposes to develop a set of tools that allows the clinicians to follow specific PSLs over time regardless
of participants’ pose and weight changes between the trials. Such a system will enable clinicians to accurately
monitor patients’ PSLs, observe changes in previously identified lesions, and become aware of newly formed
lesions at the point of care. The ultimate goal of this project is to develop a skin cancer screening tool.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government